Characterization of human breast tissue microbiota from core needle biopsies through the analysis of multi hypervariable 16S-rRNA gene regions by Costantini, L. et al.
1ScIentIfIc RepoRTs |         (2018) 8:16893  | DOI:10.1038/s41598-018-35329-z
www.nature.com/scientificreports
Characterization of human breast 
tissue microbiota from core needle 
biopsies through the analysis of 
multi hypervariable 16S-rRNA gene 
regions
Lara Costantini  1, Stefano Magno2, Davide Albanese  3, Claudio Donati3, Romina Molinari  1, 
Alessio Filippone2, Riccardo Masetti2,4 & Nicolò Merendino1
Breast microbiota compositions are not well understood, and a few recent reports have begun to 
explore the correlation between breast tissue dysbiosis and cancer. Given that various methods for 
breast microbiota detection were used, the aim of the present paper was to clarify which hypervariable 
region of the 16S-rRNA gene (V2, V3, V4, V6 + 7, V8, and V9) is the most informative for breast tissue 
microbiota. Core needle biopsies (CNBs) were compared with surgical excision biopsies (SEBs) to find 
a less invasive form of recovery useful for the analysis of a larger statistical population and potentially 
for diagnostic use of breast tissue microbiota. Finally, this study was the first to analyse the breast 
microbiota of tumours and paired normal tissues of a Mediterranean population. Our findings showed 
that the V3 region is the most informative for breast tissue microbiota, accounting for 45% of all 
reads. No significant differences were found between CNB and SEB specimens in terms of total reads 
and numbers of Operational Taxonomic Units (OTUs). Moreover, we find that more similarities than 
differences exist between tumours and adjacent normal tissues. Finally, the presence of the Ralstonia 
genus is associated with breast tissue.
Breast cancer remains the most common tumour found in women worldwide. Despite the significant therapeutic 
advances made, European breast cancer mortality predictions are estimated at 92,700 deaths for 2018 and are 
anticipated to rise to 93,300 by 20201,2. While the aetiology of this malignancy remains unclear, like other cancers, 
it is a multifactorial disease that likely emerges from a combination of genetic and non-hereditary factors. Among 
non-hereditary factors, microbiota are attracting considerable interest3. It is estimated that 15% to 20% of cancer 
cases are driven by microbial pathogens and that even more malignancies are associated with an altered com-
position of microorganisms that colonize human tissues, referred to as dysbiosis4. Studies based on gnotobiotic 
animal models support the presence of oncogenic activity related to dysbiosis, proving the cancerous or tumour 
suppressive activities of certain bacterial strains5,6. Nevertheless, most of these studies are associative, and as such, 
they cannot determine whether dysbiosis is a cause or consequence of the onset of the disease. For this reason, the 
causal relationship between microbiota and cancer remains unclear.
In addition to exploring bacterial entry from the nipple (from the skin, from lactation, and from sexual con-
tact)7,8, some studies have proposed the presence of a gut-breast axis along which bacteria present in the maternal 
gut may reach the mammary gland through an endogenous route involving dendritic cells9. Moreover, further 
studies show that mammary dysbiosis may lead to the formation of lactational mastitis, an inflammation of mam-
mary gland in which opportunistic pathogenic bacteria outgrow healthy commensal bacteria10. Evidence shows 
that the treatment of lactational mastitis with orally administered probiotics recovered from human milk is more 
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effective than antibiotic and then it supports the presence of a gut-breast axis11. However, breast microbiota com-
positions are not well understood, and only recently have works begun to explore the correlation between breast 
tissue dysbiosis and cancer. These works agree that breast tissues have unique microbiota distinct from other 
body sites and characterized by a predominance of Proteobacteria as the most abundant phylum followed by 
Firmicutes12,13. However, to date, it is not clear if a difference between tumour and paired normal tissues within 
the breast does exist12,14. In addition, existing studies on breast tissue microbiota have applied different detection 
methods, and it is thus difficult to compare them. Recent evidence shows that the microbiota of normal tissues 
are more similar to those of adjacent tumour tissues than to the microbiota of breast tissues of women without 
cancer15. This phenomenon may be interpreted in two different ways: dysbiosis is antecedent to carcinogenic 
events and can establish a microenvironment prone to cancer or there is no correlation between the two events. 
However, knowledge of the microbiota of breast cancer patients remains in its infancy. Given this context, further 
studies must be conducted to understand which of the two possibilities occurs in cases of breast cancer.
Considering that breast tissue microbiota have been poorly characterized and with several methods, the first 
aim of the present work was to clarify which hypervariable region of the 16S-rRNA gene is the most descriptive 
for breast tissue microbiota by returning the highest number of sequenced reads and by detecting phyla identified 
in previous works12,13. The most informative region was in turn used for breast tissue characterization. In addi-
tion, with a view to the diagnostic use of microbiota, we compared the bacterial content of tissues derived from 
surgical excision biopsies (SEBs) using a less invasive recovery technique involving core needle biopsies (CNBs) 
drawn from patients with diagnosed with breast cancer. For this purpose, fresh tissue samples of both cancer and 
paired healthy tissues were collected from CNBs and SEBs to evaluate if the former has the same resolving power 
as the most invasive SEB procedure. Finally, we for the first time analysed the breast microbiota of tumour and 
paired normal tissues of a Mediterranean population.
Results
Hypervariable region selection. The first taxonomic identification of 32 collected specimens (six samples 
from patients that underwent both SEB and CNB procedures were discarded from CNB group) was carried out 
on reads obtained via the amplicon sequencing of seven hypervariable regions of the 16S-rRNA gene (V2, V3, 
V4, V6 + V7, V8, and V9). Total read counts drawn from the CNB (median 475,337) and SEB (median 609,335) 
sampling methods were not significantly different (p = 0.33). As was expected, amplicons ranged in size from 200 
to 300 bp with a mean read length of 213.22 ± 21.07 bp.
The environmental control samples collected to identify potential contaminations involved due to specimen 
exposure to the external environment contained an undetectable amount of microbial gDNA.
An analysis of the amplified regions shows that the percentage of reads was not homogeneous across the 
hypervariable regions. Indeed, 45% of the reads were drawn from the V3 region followed for the V4, V6 + V7, 
V2, and V8 regions (21%, 13%, 12%, and 9% of the reads, respectively). The V9 region was the less informa-
tive, contributing less than 0.1% of the sequencing reads (Fig. 1, panel a). Similar proportions of mapped reads 
were also found from sampling and tissue type groups (see Supplementary Fig. S1). The percentage of each 
found phylum was evaluated for each hypervariable region (Fig. 1, panel b). The presence of four major phyla 
(Proteobacteria, Firmicutes, Actinobacteria, and Bacteroidetes) was supported by all of the analysed hypervar-
iable regions (Fig. 1, panel b), and the estimated proportions of each phylum were found to be comparable. 
We thus obtained comparable estimates of sample biodiversity from the different hypervariable regions. Across 
the regions, the Proteobacteria phylum was the most abundant followed by Firmicutes, Actinobacteria, and 
Bacteroidetes, respectively. Indeed, 85% of the reads mapped onto the V3 region were classified as belonging to 
phylum Proteobacteria, 11% belonged to Firmicutes, and the rest belonged to Actinobacteria and Bacteroidetes 
(Fig. 1, panel b). Likewise, for all reads belonging to the V4 region, the region with the second most reads, 83% 
of reads were classified as deriving from the Proteobacteria phylum, 11% derived from Firmicutes, and the rest 
derived from Bacteroidetes and Actinobacteria (Fig. 1, panel b). The only difference found between the V3 and V4 
Figure 1. Comparison of the efficiency of analysed hypervariable regions of the 16S-rRNA gene (n = 32). 
(a) Distribution of obtained total read counts for each analysed hypervariable region. (b) Evaluation of read 
distributions of the analysed 16S-rRNA gene hypervariable regions and of each phylum found to compare the 
informative power of the regions. In both panels values are presented as relative abundances as percentages of 
total read counts obtained by combining data drawn for all of the analysed specimens (both SEBs and CNBs, 
healthy and cancerous).
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regions concerning phyla proportions was an enhanced detection of Actinobacteria for the V3 region against an 
increased level of Bacteroidetes found for the V4 region, although this involved only 0.5% and 1.6% of all reads, 
respectively (Fig. 1, panel b). Completely different results were found for the V9 region, which presented lower 
levels of biodiversity with only taxa of the Proteobacteria phylum (Fig. 1, panel b).
Microbiota analysis. From the analysis of the most informative hypervariable region we used one region 
to conduct our microbiota analysis to avoid systematic biases16. Therefore, the V3 region was selected given that 
it was the region to which the largest number of reads (45%) belonged (Fig. 1, panel a). A dataset of 12,668,490 
reads was generated with a mean coverage of 70,223.42 reads per sample. Sampling heterogeneity was reduced 
by rarefaction (without replacements) to 4500 reads per sample. One tumour SEB sample with less than 4500 
reads and the paired normal SEB sample were discarded. Six samples from patients that underwent both SEB and 
CNB procedures were discarded from CNB group. Breast microbiota of the paired normal and tumour tissues of 
9 patients undergoing CNBs and of 6 patients subjected to SEBs were surveyed for a total of 30 specimens. After 
rarefaction, a total amount of 738 operational taxonomic units (OTUs) was obtained based on 97% sequence 
similarity (see Supplementary Dataset S1). The number of observed OTUs was not significantly different among 
healthy tissues and paired tumour tissues of SEBs (medians: 130 for healthy tissues and 119 for cancerous tissues), 
and of CNBs (medians: 125 for healthy tissues and 127 for cancerous tissues) (p = 0.0684 and p = 0.0922 SEBs and 
CNBs, respectively, generalized linear model17, quasi-Poisson families), revealing no significant difference in rich-
ness between the two classes of samples (Fig. 2, panel a; Supplementary Dataset S2). Similarly, between subjects, 
the number of observed OTUs was not significantly different among SEBs and CNBs of healthy and cancerous 
tissues (p = 0.816 and p = 0.434, for healthy and cancerous tissues respectively, generalized linear model, Poisson 
family). The differences were not found to be significant when applying Shannon entropy (p = 0.69 and p = 0.379 
for healthy and cancerous tissues, respectively, generalized linear model, Gaussian family).
The Shannon diversity index did not show significant differences between healthy-adjacent and tumour tis-
sues for both CNBs and SEBs (p = 0.959 and p = 0.0547, respectively, linear model, Gaussian family) (Fig. 2, 
panel b). Weighted UniFrac distances were calculated to investigate dissimilarities (beta-diversity) between the 
SEB and CNB samples of both healthy-adjacent and cancer tissues. The survey shows that differences found 
within subjects (i.e., distances between healthy-adjacent and cancerous samples for each subject) were signifi-
cantly less pronounced than those found between subjects for both healthy-adjacent (p = 6.78 × 10−5) and can-
cerous tissues (p = 2.02 × 10−4, Wilcoxon rank-sum test, FDR corrected p values - Fig. 3, panel a). Moreover, no 
significant differences were found when comparing all healthy-adjacent tissues to all cancerous tissues (p = 0.84). 
In support of this, a principal coordinate analysis (PCoA) of weighted UniFrac distances showed no clear divi-
sions between tumour and healthy-adjacent tissues (Fig. 3, panel b). PCoA (using weighted UniFrac distances) 
Figure 2. Alpha-diversity analysis after rarefaction (n = 30). A comparison of the two alpha-diversity measures 
for the two tissue and sampling types: (a) number of observed OTUs, (b) Shannon index.
www.nature.com/scientificreports/
4ScIentIfIc RepoRTs |         (2018) 8:16893  | DOI:10.1038/s41598-018-35329-z
was also used to highlight differences correlated with histoprognostic grade and molecular subtypes of tissue 
samples (see Supplementary Fig. S2). However, even in this case, no clear segregation of samples was found. 
Finally, taxonomic identification at the family/genus level for each individual patient was carried out to better 
understand differences found in the examined population (Fig. 4). Confirming the previous taxonomic analysis, 
OTUs found in the V3 region belonged to the four different phyla (Proteobacteria, Firmicutes, Bacteroidetes, 
and Actinobacteria). As is shown in Fig. 4, roughly 50–75% of relative abundances belonged to Ralstonia, 
Methylobacterium, and Sphingomonas genera (see Supplementary Dataset S3). The remaining 25–50% were 
mainly constituted by Staphylococcus and Pseudomonas genera and by Bradyrhizobiaceae and Rhodocyclaceae 
families (see Supplementary Dataset S3 and S4). To confirm the beta-diversity analysis shown in Fig. 3, the rela-
tive abundance of cancerous and healthy-adjacent tissues drawn from the same patient was found to be essentially 
the same while major differences were found among different subjects. Nevertheless, in some cases differences 
were also found in the same patient. For example, cancerous samples B5, and B8 showed an increase in the relative 
abundance of Methylobacterium and a decrease in the relative abundance of Sphingomonas in comparison to their 
healthy counterparts. Similarly, cancerous samples A5, A6, and A8 showed a decrease in the relative abundance 
of Methylobacterium concomitant with an increase in the Ralstonia genus relative to the healthy controls. These 
differences were not found in the other subjects.
Discussion
While the presence of specific microbiota in human milk has been known for several years18, only in the last 
few years breast tissue microbiota have been evaluated irrespective of lactation and in correlation with can-
cer12–15,19–21. Such studies have been made possible with the use of next-generation sequencing (NGS) technol-
ogies, which allow for the simultaneous analysis of large volumes of genetic material drawn from uncultivable 
bacteria in cost-effective and time-saving modalities22. However, considerable differences in methodologies used, 
e.g., specimen treatment after collection, gDNA isolation, target hypervariable region selection for sequencing, 
and sequence analysis workflows, have resulted in considerable heterogeneity in results, delaying the assessment 
of the existence of a link between dysbiosis and breast cancer. For example, there is a lack of consensus regarding 
which hypervariable region to amplify for breast tissue microbiota description. It is know that specific hypervari-
able regions are more likely to identify certain taxa23 and that because different microenvironments are colonized 
by different microbial populations, the amplification of a hypervariable region solely due to its specific use for 
another biological niche is inappropriate. To date there is no evidence regarding which hypervariable region is 
the most representative for describing breast tissue microbiota. Such an assessment appears fundamental to the 
correct characterization of this new microenvironment.
To shed light on this issue, we for the first time simultaneously analysed seven hypervariable regions of the 
16S-rRNA gene (V2, V3, V4, V6 + V7, V8, and V9) to identify the hypervariable region producing the most reads 
in the same workflow. We found the V3 region to be the most representative in terms of read counts, accounting 
for 45% of all reads, while the V8 and V9 regions contribute to the fewest reads. According to these data, even 
though regions V4 and V6 + V7 are the most informative for gut microbiota description24, the use of the same 
regions to describe breast tissue microbiota could underestimate the totality of the analysed population12,14,19,20. 
Figure 3. Dissimilarity analysis (beta-diversity) of the healthy and cancerous CNB and SEB samples. (n = 30). 
(a) The weighted UniFrac distance was used to analyse distances between cancerous and healthy samples of 
different subjects (between subjects, BS) in comparison to healthy and cancerous samples of the same subject 
(within subject, WS). (b) Principal coordinate analysis (PCoA) based on Weighted UniFrac distances.
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Instead, the strategy adopted in the most recent studies of Hieken et al., 2016, Wang et al., 2017, and Thompson 
et al., 2017 using primers that cover the entire V3-V5 region appears to be the best strategy as confirmed by the 
present study, from which we found the V3 and V4 regions to identify 45% and 21% of examined reads, respec-
tively13,15,21. Moreover, this choice may overcome minor differences that we found between the identification of 
Actinobacteria and Bacteroidetes from the V4 and V3 regions (Fig. 1, panel b). In support of this, a study com-
paring several hypervariable regions to describe oral microbiota shows that it is important to use the V1-V3 and 
V7-V9 regions to obtain results similar to those of 16S-rRNA gene Sanger sequencing25. Nevertheless, even if the 
use of multiple hypervariable regions seems to be the best strategy for describing a complex community, to the 
best of our knowledge no method yet combines OTUs across multiple variable regions26. In summary, V3 region 
sequencing can provide a fairly complete account of breast tissue microbiota and especially when the amplifica-
tion of small regions of DNA is desirable. In other cases, the sequencing of an amplicon covering both V3 and V4 
regions is more appropriate at higher resolutions27. Finally, in light of the present findings, future applications of 
the same analysis even for the V1 and V5 regions could help to complete our overview and eventually confirm 
that the V3 region is the most informative of breast tissue microbiota.
More detailed analyses of the specimens considered in this study were carried out on the V3 region. Both our 
multiple hypervariable region evaluation and V3 analysis show that breast tissue microbiota do not have compa-
rable compositions to those of other body sites (e.g., the gut, skin, vagina, oral cavity, and bladder)28–32. Indeed, 
in this tissue niche Proteobacteria constitute the most abundant phylum followed by Firmicutes, Actinobacteria, 
and Bacteroidetes in descending order (Fig. 1, panel b). On the other hand, we find evident similarities with 
human milk for which Proteobacteria is also the most abundant phylum followed by the other phyla (Firmicutes, 
Actinobacteria, and Bacteroidetes, respectively)33. These findings complement those of previous studies conducted 
on breast tissue microbiota12,13,19.
The second aim of the present study was to compare samples drawn from CNBs with those obtained from 
conventional surgical biopsies, SEBs, to determine if the former can apply the same level of resolving power as 
the most invasive surgical procedure. The procedure from which CNBs can be obtained allows for a more limited 
contamination of specimens even if the tissue levels are lower than those of SEBs. Indeed, even though breast 
tissues drawn from SEBs were obtained under fully aseptic conditions, surgical excision involves an unavoidable 
exposure to the external environment34,35. However, in the present study, the collection of environmental controls 
showed that such external contamination was undetectable.
Our findings show that no significant differences in total read counts and number of OTUs were found 
between our CNB and SEB specimens, thus exhibiting their equal capacity to describe breast tissue microbiota. 
Then, since CNBs are obtained from a less invasive procedure, this may be used as a predictive tool for the eval-
uation of potential dysbiosis in concomitance with the determination of histoprognostic grade and hormone 
receptor status even in a screening population study36.
Finally, the ultimate goal of the present study was to evaluate if differences exist between cancerous and paired 
normal tissues drawn from CNB and SEB specimens. We first found no differences in the number of OTUs 
in normal tissues than in paired tumour tissues for both CNBs and SEBs, suggesting a same level of richness 
between tumour tissues and healthy-adjacent tissues (Fig. 2, panel a). Similarly, our biodiversity analysis of alpha- 
and beta-diversity levels did not reveal significant differences between cancerous and paired normal tissues (Fig. 2 
panel b; Fig. 3). However, differences between healthy and cancerous tissues drawn from the same patient in com-
parison to differences between healthy and cancerous tissues drawn from all of the analysed patients were found 
to be significant, indicating that there are more differences between subjects than between healthy and cancerous 
tissues collected from the same patient (Fig. 3, panel a). The fact that bacterial diversity within samples varies 
Figure 4. Relative abundances measured at the genus and family levels. Barplots of the taxonomic profiles 
with each bar representing a subject and with each coloured box showing a bacterial taxon. (a) Barplots of each 
specimen measured at the genus level; (b) barplots of each specimen measured at the family level.
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most between individuals was also found by Urbaniak et al., 201412. The observation that more similarities than 
differences exist between tumour and adjacent normal tissues is in agreement with the results of Wang et al., 2017 
who found that invasive carcinoma and paired normal tissues show no major shifts in overall diversity or micro-
biomic content15. Similar results were found by Urbaniak et al., 2016 who found normal tissues from women with 
benign tumours to be more similar to normal adjacent tissues from cancer patients than to normal tissues from 
healthy women19. Given that previous studies have highlighted differences between normal tissues of cancer and 
non-cancer patients12,15,19 and between nipple aspirate fluids in women with or without a history of breast can-
cer20, the presence of similar microbiota in cancerous and paired normal tissues could indicate a predisposition 
to carcinogenesis as previously suggested15. Applying such results to a larger population could thus involve using 
the microbiota analysis of breast tissues obtained with CNB as a predictive tool for measuring breast cancer risk.
In support of variability found between individuals, relative abundance measured at the family/genus level 
for each individual patient was assayed (Fig. 4). We are the first to find that the presence of genus Ralstonia, 
Proteobacteria phylum, is the most abundant genus found in breast tissue while the presence of this genus had 
previously only been related to human milk7. This finding may be attributed to procedures used for microbial 
gDNA isolation and analysis, which likely allow for a greater recovery of useful gDNA and for its more accurate 
analysis. Indeed, samples were obtained under aseptic conditions and were freshly processed to limit contami-
nation and genetic material loss as is found in frozen and formalin-fixed paraffin-embedded tissues37. Moreover, 
most gDNA from living microbes was isolated, removing non-target DNA as free floating and human DNA38. 
Finally, the most representative hypervariable region of the 16S-rRNA gene V3 was used to perform a metagen-
omic analysis. In turn, these procedures likely allowed us to secure a better description of the target microbial 
population. In addition, in this study, breast tissue microbiota of the Italian population (with geographic, racial, 
and dietary differences compared to previously analysed populations) were analysed for the first time39.
It is noteworthy that among this population, three patients showed a decrease in the relative abundance of 
Methylobacterium concomitant with an increase in the Ralstonia genus. However, the only correlation between 
Ralstonia dysbiosis and cancer cited in the literature is related to gastric cancer40 while a correlation with breast 
cancer has never been investigated.
Following Ralstonia in terms of abundance, the presence of Methylobacterium and Sphingomonas genera in 
Proteobacteria phylum was confirmed consistent with Xuan et al., 2014, Urbaniak et al., 2014, and Wang et al., 
201712,14,15. In two patients we also found differences between paired normal and cancerous tissues where the rel-
ative abundance of Methylobaterium in cancerous tissues increases while the relative abundance of Sphingomonas 
decreased in comparison to the healthy counterparts as shown in prior studies12,14,15. These differences were not 
found in all of the analysed patients and for this reason they are not deemed statistically significant.
Given strong inter-individual variations found in breast bacterial compositions, it could be assumed that 
breast tissue microbiota can fall into distinct group types and that the dysbiosis of these different taxa inevitably 
spurs a different interplay of polymicrobial interactions that in correlation with genetic predispositions and/or 
hormone receptor statuses could drive the establishment of a carcinogenic event.
This study is limited by the small sample size used and as discussed above through our exclusion of V1 and 
V5 regions from the analysis. Future studies of larger samples must be conducted to confirm with confidence a 
correlation between microbiota and breast cancer with reference to a positive control of normal tissue drawn 
from healthy individuals.
Nevertheless, the present study showed that the V3 hypervariable region of the 16S-rRNA gene among the 
other six analysed regions (V2, V4, V6 + V7, V8, and V9) presents the largest number of mapped reads between 
the CNB and SEB samples. Percutaneous breast biopsies (CNBs) appear to be reliable and safe clinical tools for 
sufficiently obtaining (even if with a smaller tissue samples) thorough microbiota descriptions of breast tissues 
comparable to those generated from more invasive procedures such as surgical biopsies (SEBs). Finally, similar 
microbiota were found in cancerous and surrounding normal tissues, suggesting that when dysbiosis occurs, it is 
an antecedent to a carcinogenic event and may establish a microenvironment prone to cancer. In any case, breast 
microbiota and their correlations with cancer remain unclear, and further studies of larger populations must be 
conducted to understand this relationship. Given this context, as CNBs are less invasive than SEBs, and the form 
could allow for the collection of a larger number of samples as was done through the Human Microbiome Project; 
this approach could be used to help clarify whether breast tissue dysbiosis may contribute to carcinogenesis. 
Following such clarifications and confirmations, CNB may prove useful as a predictive tool for the dysbiosis 
evaluation of the healthy population.
Methods
Ethics statement and patient enrolment. CNBs and SEBs of fresh breast tissues were obtained from 
patients diagnosed with breast cancer undergoing surgical treatment at the Fondazione Policlinico Universitario 
Agostino Gemelli IRCCS in Rome, Italy. Ethical approval for this study was obtained from the ethics committee 
of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (approval number: 8407/18 ID: 1915) and 
all methods were performed in accordance with all relevant guidelines and regulations. Patients provided written 
informed consent for sample collection and subsequent analysis. Clinical and biological patient data (age, BMI, 
menopausal status, menarche advent, number of pregnancies, comorbidity, family history of breast cancer, hor-
mone therapy compliance, histoprognostic grade, hormone receptor status (Estrogen Receptor, ER; Progesterone 
Receptor, PR; Human Epidermal Growth Factor Receptor 2, HER2; Ki-67)) and molecular subtypes were col-
lected and are listed in Table 1. Patients eligible to participate in the study were females of over 18 years of age with 
tumours larger than or equal to 2 cm in size who had not been subjected to any current pharmacological cancer 
treatments and who had no active clinical breast infections or necrotic tissues.
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Tissue collection and processing. CNB and SEB specimens were collected from 16 patients (12 for CNBs 
and 7 for SEBs, three patients underwent both procedures). For both samples (i.e., CNBs and SEBs), both tumour 
and healthy adjacent tissues were collected for a total of 38 specimens. For CNBs, two imaging-guided sampling 
approaches involving the use of two different sterile semiautomatic devices equipped with 14-gauge needles were 
applied to tumour and paired normal tissues after skin surface disinfection with povidone-iodine (Betadine). For 
tumour SEBs, a slice of each tumour mass radial section was collected under sterile conditions after tumour masses 
were excised (i.e., neoplastic tissue surrounded by a marginal zone) from the patients in an operating room under 
aseptic conditions. To avoid cross-contamination, a different disposable sterile scalpel from that used for excision 
was used to obtain the tumour section. For both procedures, healthy adjacent tissue was collected from outside of 
the marginal zone positioned approximately 5 cm away from the tumour’s edge. After both excisions were made, 
fresh tissues (approximately 15 mg and 200 mg for CNBs and SEBs, respectively) were immediately placed in sterile 
study code-labelled DNA-free vials on ice and were processed within 3 hours of collection. As an environmental 
control, for both surgical procedures, a tube filled with 200 μL of TSB buffer (Ultra-Deep Microbiome Prep, Molzym, 
Bremen, Germany) was left open until an excision was made and it was then processed as the tissues specimens 
were. Both CNB and SEB fresh tissue samples were cut into small pieces (less than 0.2 × 0.2 cm) with a sterile scalpel 
under sterile conditions. Immediately thereafter, microbial genomic DNA (gDNA) isolation was performed.
Microbial gDNA isolation. To remove non-target DNA, an Ultra-Deep Microbiome Prep kit (Molzym, 
Bremen, Germany) was used according to the manufacturer’s protocol. This allowed us to degrade free floating 
and human DNA and to isolate gDNA from living microbes in fresh clinical samples. All extractions were per-
formed with the same kit lot, in a designated clean pre-PCR area using DNA-free reagents and consumables. 
The concentration of the obtained microbial gDNA samples was estimated using a Qubit 3.0 Fluorometer (Life 
Technologies, Carlsbad, CA, USA) and Qubit dsDNA HS Assay Kit (Life Technologies, Carlsbad, CA, USA). The 
gDNA samples were then stored at −20 °C until further use.
Preparation of samples and sequencing of 16S-rRNA gene amplicons. gDNA drawn from each 
clinical sample was amplified using an Ion 16S Metagenomic Kit (Life Technologies, Carlsbad, CA, USA). Using 
this kit we amplified seven of nine hypervariable regions of the 16S-rRNA gene through two sets of primers: one 
CNBs SEBs Total
Number of patients 9 7 16
Age – average (range) 55 (46–71) 65 (46–82) 59 (46–82)
BMI – average (range) 24.6 (18.8–28.2)
27.8 
(20.8–36.5)
26.0 
(18.8–36.5)
Pre-menopausal – n (%) 1 (11.1%) 1 (14.3%) 2 (12.5%)
Peri-menopausal – n (%) 2 (22.2%) 1 (14.3%) 3 (18.8%)
Post-menopausal – n (%) 6 (66.7%) 5 (71.4%) 11 (68.8%)
Menarche – average (range) 13.1 (11–17) 12.1 (10–16) 12.7 (10–17)
Pregnancy – n (%) 8 (88.9%) 7 (100%) 15 (93.8%)
Number of pregnancies – average (range) 1.7 (0–4) 2.3 (2–4) 2.1 (0–4)
Comorbidity – n (%) 4 (44.4%) 5 (71.4%) 9 (56.3%)
Family history of breast cancer – n (%) 3 (33.3%) 2 (28.6%) 5 (31.3%)
Hormone therapy – n (%) 1 (11.1%) 2 (28.6%) 3 (18.8%)
Grade G1– n (%) 0 (0.0%) 1 (14.3%) 1 (6.3%)
Grade G2 – n (%) 8 (88.9%) 3 (42.9%) 11 (68.8%)
Grade G3 – n (%) 1 (11.1%) 3 (42.9%) 4 (25.0%)
Estrogen Receptor positive (ER+) – n (%) 8 (88.9%) 6 (85.7%) 14 (87.5%)
Estrogen Receptor negative (ER−) – n (%) 1 (11.1%) 1 (14.3%) 2 (12.5%)
Progesterone Receptor positive (PR+) – n (%) 8 (88.9%) 6 (85.7%) 14 (87.5%)
Progesterone Receptor negative (PR−) – n (%) 1 (11.1%) 1 (14.3%) 2 (12.5%)
Human Epidermal Growth Factor Receptor 2 positive (HER2+) – n (%) 1 (11.1%) 0 (00.0%) 1 (6.2%)
Human Epidermal Growth Factor Receptor 2 negative (HER2−) – n (%) 8 (88.9%) 7 (100%) 15 (93.8%)
High Ki-67 (H-Ki-67) – n (%) 8 (88.9%) 5 (71.4%) 13 (81.2%)
Low Ki-67 (L-Ki-67) – n (%) 1 (11.1%) 2 (28.6%) 3 (18.8%)
Luminal A (ER+/PR+/HER2−/ L-Ki-67) – n (%) 1 (11.1%) 2 (28.6%) 3 (18.8%)
Luminal B/ HER2- (ER+/PR+/HER2+) – n (%) 7 (77.8%) 4 (57.1%) 11 (68.8%)
HER2-like (ER−/PR−/HER2+) – n (%) 1 (11.1%) 0 (00.0%) 1 (6.2%)
Triple negative (ER−/PR−/HER2−) – n (%) 0 (0.0%) 1 (14.3%) 1 (6.2%)
Table 1. Characteristics of and clinical data on the volunteers. Data are expressed as the means with ranges 
shown in brackets (i.e., min and max values) or as the number of subjects (shown in brackets) of the relative 
percentage of subjects. High Ki-67: positive cells to Mib1 antibody ≥20%; Low Ki-67: positive cells to Mib1 
antibody <20%. CNBs: core needle biopsies; SEBs: surgical excision biopsies; BMI: body mass index.
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set for the V2, V4, and V8 regions and the other for the V3, V6 + V7, and V9 regions. The PCR was performed by 
preparing two reactions for each clinical sample for each of the two primer sets using a PCR Sprint thermocycler 
(Thermo Hybaid, Ashford, UK) following the kit manufacturer’s instructions. Amplification products of each 
set were then pooled in equimolar amounts and the final mixtures were purified using magnetic beads of the 
Agencourt AMPure XP Reagent (Beckman Coulter, Beverly, MA, USA). We then used 2 μL of each mixture to cal-
culate the DNA input for library preparation using the Qubit dsDNA HS Assay Kit (Life Technologies, Carlsbad, 
CA, USA). Concentrations of 10–100 ng in 79 μL of dilution buffer were used to prepare libraries using the Ion 
Plus Fragment Library Kit (Life Technologies, Carlsbad, CA, USA). This allowed us to first execute end-repair 
procedures and then to ligate adapters after purification and perform nick-repairs. As different clinical samples 
were combined into pooled libraries, barcoded adapters were employed via the Ion Xpress Barcode Adapters Kit 
(Life Technologies, Carlsbad, CA, USA). After an additional purification step, 50 ng of the obtained library was 
amplified to enhance the presence of amplicons with heterogeneous adapters (P1-X, rather than P1-P1 or X-X) 
following the kit manufacturer’s instructions (Ion Plus Fragment Library Kit, Life Technologies, Carlsbad, CA, 
USA). After another purification step, each library was quantified using the Qubit dsDNA HS Assay Kit (Life 
Technologies, Carlsbad, CA, USA) and was pooled to the correct dilution. For template preparation on Ion Sphere 
Particles (ISPs), pooled libraries were subjected to emulsion PCR performed using the Ion PGM Hi-Q View OT2 
Kit (Life Technologies, Carlsbad, CA, USA) and the Ion One Touch 2 System instrument (Life Technologies, 
Carlsbad, CA, USA). Only template-positive ISPs were then selected with Ion PGM Enrichment beads (Life 
Technologies, Carlsbad, CA, USA) using the Ion One Touch ES instrument (Life Technologies, Carlsbad, CA, 
USA). Finally, positive ISPs for all of the samples and controls were randomly loaded onto six different Ion 316 
Chips v2 BC (Life Technologies, Carlsbad, CA, USA) and were sequenced with an Ion PGM Sequencer using an 
Ion PGM Hi-Q View Sequencing Kit (Life Technologies, Carlsbad, CA, USA).
Sequence analysis. BAM files obtained from Ion PGM Sequencer output were directly processed with Ion 
Reporter Software 5.6 (Life Technologies, Carlsbad, CA, USA). Within this programme, the 16S Metagenomic 
workflow works with MicroSEQ(R) 16S Reference Library v2013.1 and Greengenes v13.5 databases to align and 
obtain a taxonomic identification of sequences. Raw data were first analysed with Ion Reporter Software 5.6 
(Life Technologies, Carlsbad, CA, USA) to obtain information on relative taxonomic abundances from primers. 
Statistical significance between read counts of the different sampling types was calculated through a t-student test.
OTU analyses were then performed on hypervariable region V3, as this region generated the most reads. 
Raw reads were pre-processed using micca41, which makes extensive use of VSEARCH42 for OTU clustering 
and sequence manipulation. Raw V3 sequences were extracted using the micca trim command with primers 
5′-ACTCCTACGGGAGGCAGCAG-3′ and 5′-CCAGCAGCCGCGGTAATAC-3′. Sequences were truncated at 
240 bp and reads with an expected error rate43 of greater than 0.5% were discarded. Sequences were clustered 
(applying the de novo greedy algorithm available through micca) at 97% identity and chimeric OTUs were dis-
carded. Taxonomy was assigned to OTUs using the RDP classifier44 (version 2.11) wrapper. Multiple sequence 
alignment was performed using the Nearest Alignment Space Termination45 (NAST) algorithm and a phyloge-
netic tree was inferred from the FastTree wrapper available through micca. Alpha diversity was modelled with 
generalized linear models through the R stats package. P-values were not corrected for multiple testing.
Data Availability
Datasets generated through the current study are available from the corresponding author on reasonable request.
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